Article

Men with Testicular Cancer More Likely to Develop Prostate Cancer

Author(s):

A new study has shown that men with a history of testicular cancer have a higher incidence of developing prostate cancer, including intermediate or high-risk prostate cancer, compared to those without a history of testicular cancer.

Mohummad Minhaj Siddiqui, MD

A new study has shown that men with a history of testicular cancer have a higher incidence of developing prostate cancer, including intermediate or high-risk prostate cancer, compared to those without a history of testicular cancer.

Senior study author Mohummad Minhaj Siddiqui, MD, discussed the results of the study during a presscast in advance of the 2015 Genitourinary Cancer Symposium, which will be held in Orlando from February 26-28.

“Men with a history of testicular cancer should talk with their doctor about assessing their risk for prostate cancer, given there may be an increased risk,” said Siddiqui, an assistant professor of surgery at the University of Maryland School of Medicine and director of urologic robotic surgery at the University of Maryland Marlene and Stewart Greenebaum Cancer Center. “It is too soon to make any practice recommendations based on this single study, but the findings provide groundwork for further research into the biologic link between the two diseases.”

While previous studies have also shown an increased rate of prostate cancer in men with a history of testicular cancer, this is the first study that looked at the likelihood of developing intermediate to high-risk prostate cancer in these patients.

For the study, researchers analyzed SEER data from 32,435 men over the age of 40 with a history of testicular cancer and compared that to a control group of 147,044 men over the age of 40 who had a history of melanoma, since there is no known association between melanoma and prostate cancer.

Intermediate to high-risk prostate cancer was defined by a Gleason score of 7 or that greater than or equal to 8, Siddiqui said.

Out of nearly 180,000 men in this study, it was found that 3,205 were diagnosed with prostate cancer. The analysis showed that the overall incidence of prostate cancer by the age of 80 was 12.6% in the men with a history of testicular cancer compared to 2.8% of men who didn’t have a history of testicular cancer (P < .0001).

A sub-analysis of men with intermediate to high-grade prostate cancer showed that the incidence of intermediate to high-grade prostate cancer by age 80 was 5.8% in the testicular cancer cohort compared to 1.1% in the control group (P < .0001).

“Now we looked at alternate risk factors, such as age, race and radiation history and found that even when controlling for the influence of these risk factors, there was still an increased risk of developing intermediate to high-risk prostate cancer in men with a history of testicular cancer as opposed to the control population,” Siddiqui said.

Since the study showed an increased risk of all types of prostate cancer in men with a history of testicular cancer, Siddiqui suggested that men with a history of prostate cancer should discuss the risk and benefits of prostate cancer screening with their doctors.

However, before changing any guidelines or recommendations, further validation studies are needed to confirm the study’s results and to determine if men with a history of testicular cancer should be screened more closely for prostate cancer.

<<<

View more from the 2015 Genitourinary Cancers Symposium

Related Videos
Jacob Sands, MD, oncology medical director, International Patient Center, Dana-Farber Cancer Institute; assistant professor, Harvard Medical School
Fred R. Hirsch, MD, PhD, executive director, Center for Thoracic Oncology, The Tisch Cancer Institute at Mount Sinai; Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology), Icahn School of Medicine at Mount Sinai
Jun Gong, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Marc-Oliver Grimm, MD
Sheldon M. Feldman, MD